FRANKREICH

BROADPEAK SA: 2024 Financial Calendar

Retrieved on: 
Mercredi, mars 13, 2024

Dissemination of a French Regulatory News, transmitted by EQS Group.

Key Points: 
  • Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • Broadpeak (ISIN: FR001400AJZ7 - Ticker Code: ALBPK), a leading player in software solutions dedicated to video streaming, announces its next financial publication dates for 2024.
  • 2024 FIRST HALF YEAR REVENUE July 24, 2024, after market close
    2024 FIRST HALF YEAR RESULTS September 26, 2024, after market close

BILENDI: 2023 annual revenues: 62,7 M€, Organic growth at constant exchange rates: +4.5% in Q4, +2.7% over the full year

Retrieved on: 
Mercredi, mars 13, 2024
TISP, Quantitative research, AI, Intelligence, Growth, Language, Harvard University, ChatGPT, University, Trust, Data collection, Market Research Society

Annual revenues for 2023 recorded a rise of +2.0%, after two record years in 2021 and 2022:

Key Points: 
  • Annual revenues for 2023 recorded a rise of +2.0%, after two record years in 2021 and 2022:
    Cumulated sales for 2023 amounts to €62.7m, an increase of +2.0% when compared to 2022.
  • After two record-breaking years of growth, 2021 (+29%) and 2022 (+39.5%), Bilendi’s strong performance in 2023 is even more remarkable.
  • Outside France (77% of total revenues), revenues amount to €48.6m, up 1.1% (2.0% at a constant exchange rate).
  • France registered three quarters of consecutive growth and ends 2023 with revenues of €14.1m, leading to a +5.2% growth in annual revenues when compared to 2022.

VAZIVA ANNOUNCES THE LISTING OF ITS STOCKS ON EURONEXT GROWTH®PARIS

Retrieved on: 
Mercredi, mars 13, 2024
SME, Fintech, Security (finance)

Paris, March 13, 2024 8:00 a.m. - VAZIVA (ISIN CODE FR0014007T10 - ALVAZ), groundbreaker in the dematerialization of social endowments, announces that it has received approval from the EURONEXT Listing Board to transfer its shares from EURONEXT Access TM Paris to the EURONEXT Growth® Paris market.

Key Points: 
  • Paris, March 13, 2024 8:00 a.m. - VAZIVA (ISIN CODE FR0014007T10 - ALVAZ), groundbreaker in the dematerialization of social endowments, announces that it has received approval from the EURONEXT Listing Board to transfer its shares from EURONEXT Access TM Paris to the EURONEXT Growth® Paris market.
  • Shares will be traded on the EA compartment (private placement) of EURONEXT Growth® Paris from March 15, 2024.
  • Vaziva has also considerably increased its share of key account business, which now accounts for 43% of sales, compared with 25% in 2022.
  • In conjunction with the transfer of VAZIVA shares from the EURONEXT Access TM Paris market to the EA listing group (private placement) on EURONEXT Growth® Paris, VAZIVA is not issuing any new shares or placing any existing shares.

RALLYE S.A.: Casino restructuring Winding-up of the holding companies

Retrieved on: 
Mercredi, mars 13, 2024

Rallye, Foncière Euris, Finatis and Euris acknowledge Paris Commercial Court’s approval of the accelerated safeguard plans for Casino and some of its relevant subsidiaries.

Key Points: 
  • Rallye, Foncière Euris, Finatis and Euris acknowledge Paris Commercial Court’s approval of the accelerated safeguard plans for Casino and some of its relevant subsidiaries.
  • The effective completion of Casino’s financial restructuring, scheduled for 27 March 2024, will result in a massive dilution for existing shareholders.
  • Thus, on completion of the restructuring, Rallye will hold 0.1% of Casino’s share capital and Rallye will therefore lose control of Casino.
  • Insofar as Rallye, Foncière Euris, Finatis and Euris safeguard plans are interdependent, Foncière Euris, Finatis and Euris will also be seeking the termination of their safeguard plan and the opening of winding-up proceedings.

Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.

Retrieved on: 
Mercredi, mars 13, 2024
Taboo, Anxiety, Woman, Mental health, Ticker, Doctor of Philosophy, EAU, Neurostimulation, Urethra, MD, Pathology, Nursing, Quality of life, Female, Prostate, Urinary incontinence, Hope, Life, European, Health, Incontinence, Medtech, Patient, Disorder, Child, Male, European Association of Urology, Trial of the century, Ageing, Animation, Wound healing, Medical device

Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.

Key Points: 
  • Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.
  • This first implantation of the artificial urinary sphincter Artus was successfully performed by Prof. Roman Zachoval, MD, PhD, head of the Department of Urology at Thomayer University Hospital in Prague, Czech Republic, on a 68-year-old male with severe urinary incontinence.
  • “Artus is easy to prepare and implant due to its innovative design compared to the previous generation of urinary sphincters.
  • Artus is an implantable artificial urinary sphincter developed for the treatment of moderate to severe urinary incontinence in both men and women.

Sartorius Stedim Biotech SA: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Retrieved on: 
Vendredi, février 16, 2024
Sartorius AG, Disclosure, BOARD, Security (finance)

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • The person making the disclosure is a closely associated person mentioned of article 3.26) of Regulation (EU) No 596/2014 of April 16, 2014 on market abuse.
  • Please give the identity and functions of the person with whom the reporting person has close personal ties.
  • Position / status: Sartorius AG legal entity related to JOACHIM KREUZBURG, CHAIRMAN OF THE BOARD and RENE FABER, CEO
    This notification is an initial notification.

Sartorius Stedim Biotech releases Universal Registration Document 2023

Retrieved on: 
Vendredi, février 16, 2024
Sartorius AG, Annual, Euronext, Euronext Paris

Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today.

Key Points: 
  • Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today.
  • Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
  • Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies.

Sartorius Stedim Biotech: Information on Document Availability

Retrieved on: 
Vendredi, février 16, 2024
Sartorius AG, Bank statement, Euronext, Euronext Paris

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Sartorius Stedim Biotech Group’s Universal Registration Document 2023 is now available at:
    It contains the following information:
    - Consolidated financial statements for the year ended December 31, 2023
    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
  • Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies.